VERTEX PHARMACEUTICALS INC | 61,72 Euro | +2,087 +3,50 % | |
| WKN: 882807 ISIN: US92532F1003 Ticker-Symbol: VX1 | Frankfurt | 17.05.13 | 15:49 Uhr |
Branche PharmaAktienmarkt NASDAQ-100NASDAQ Biotech S&P MidCap 400 |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 17.05. | VERTEX PHARMACEUTICALS INC / MA - 8-K, Current Report | 11 | SEC Filings | |
| 10.05. | Vertex Pharmaceuticals Crosses Above its 10-day MA | 46 | SmarTrend | |
| 10.05. | Vertex Pharmaceuticals kündigt Webcasts seiner Präsentationen auf zwei Anlegerkonferenzen an | 128 | Business Wire | |
| Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) gab heute bekannt, dass die Präsentationen, die das Unternehmen am Dienstag, den 14. Mai 2013 um 15.40 Uhr PT auf der Bank of America Healthcare-Konferenz... Mehr lesen zu: Vertex Pharmaceuticals kündigt Webcasts seiner Präsentationen auf zwei Anlegerkonferenzen an | ||||
| 08.05. | VERTEX PHARMACEUTICALS INC / MA - 8-K, Current Report | 21 | SEC Filings | |
| 03.05. | Vertex Pharmaceuticals Beats Analyst Expectations, Yet Insiders Continue To Sell More Shares | 92 | Seeking Alpha | |
| 01.05. | Why BioMarin, Catalyst Pharmaceutical Partners And Vertex Are Expected To Outperform | 68 | Seeking Alpha | |
| 01.05. | UBS erhöht das Kursziel für Vertex Pharma von $60 auf $86, Rating buy | 231 | BörseGo | |
| UBS erhöht das Kursziel für Vertex Pharma von $60 auf $86, Rating buy
(© BörseGo AG 2013 - Autor: Tobias Krieg, Redakteur) Mehr lesen zu: UBS erhöht das Kursziel für Vertex Pharma von $60 auf $86, Rating buy | ||||
| 01.05. | Vertex Pharmaceuticals Incorporated Management Discusses Q1 2013 Results - Earnings Call Transcript | 14 | Seeking Alpha | |
| 01.05. | UPDATE: Vertex Pharmaceuticals Swings to 1st-Quarter Loss on Write-Down | 12 | Euroinvestor | |
| 01.05. | Vertex Swings To Q1 Loss | 97 | AFX News | |
| CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX)
reported a net loss for the first quarter of $308.0 million or $1.43 per share,
compared to net income of $91.6 million... Mehr lesen zu: Vertex Swings To Q1 Loss | ||||
| 30.04. | Vertex Pharmaceuticals Swings to 1st-Quarter Loss on Write-Down | 5 | Euroinvestor | |
| 30.04. | Vertex posts quarterly loss as hepatitis C drug sales fall | 5 | Reuters.com | |
| 30.04. | VERTEX PHARMACEUTICALS INC / MA - 8-K, Current Report | 6 | SEC Filings | |
| 25.04. | Vertex gibt neue Daten bekannt, die hohe virale Heilungsraten bei einer Telaprevir-Kombinationsbehandlung von insgesamt 12 und 24 Wochen bei Hepatitis-C-Patienten (Genotyp 1) mit dem IL28B-CC-Genotyp zeigten | 261 | Business Wire | |
| Zwischenanalyse der CONCISE-Studie der Phase 3b zeigte SVR12-Raten von 87 Prozent bei einer Behandlung von insgesamt 12 Wochen und 97 Prozent bei einer Behandlung von insgesamt 24 Wochen... Mehr lesen zu: Vertex gibt neue Daten bekannt, die hohe virale Heilungsraten bei einer Telaprevir-Kombinationsbehandlung von insgesamt 12 und 24 Wochen bei Hepatitis-C-Patienten (Genotyp 1) mit dem IL28B-CC-Genotyp zeigten | ||||
| 24.04. | Vertex Pharma Reports Interim Analysis Data Of Phase 3b CONCISE Trial | 90 | AFX News | |
| CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX)
announced new data from an interim analysis of the exploratory global Phase 3b
CONCISE study assessing the potential... Mehr lesen zu: Vertex Pharma Reports Interim Analysis Data Of Phase 3b CONCISE Trial | ||||
| 24.04. | Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype | 74 | Business Wire | |
| Interim analysis of the Phase 3b CONCISE study showed SVR12 rates of 87 percent with 12 total weeks of treatment and 97 percent with 24 total weeks of treatment among people who achieved... Mehr lesen zu: Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype | ||||
| 23.04. | Vertex Pharma Says VX-135 Holds Promise For Hepatitis C | 113 | AFX News | |
| CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Incorporated,
(VRTX), a manufacturer of small molecule drugs for patients with serious
diseases, Tuesday announced a new data... Mehr lesen zu: Vertex Pharma Says VX-135 Holds Promise For Hepatitis C | ||||
| 23.04. | Netflix Indicating Big Jump Pre-Market on Earnings Surprise - Top Earnings Stocks Ahead of the Bell: Power-One Inc., Goff Corporation, AMR Corporation, Fannie Mae, Vertex Pharmaceuticals | 185 | PR Newswire | |
| LONDON, April 23, 2013 /PRNewswire/ --
Market futures are indicating a higher open on Wall Street this morning and so are shares of Netflix, Inc. (NFLX) which are currently indicating an open of... Mehr lesen zu: Netflix Indicating Big Jump Pre-Market on Earnings Surprise - Top Earnings Stocks Ahead of the Bell: Power-One Inc., Goff Corporation, AMR Corporation, Fannie Mae, Vertex Pharmaceuticals | ||||
| 23.04. | Vertex Pharma (VRTX) Reports Significant Data from VX-135 in HCV RNA | 16 | StreetInsider.com | |
| 22.04. | Vertex up more than 50% on new study on cystic fibrosis treatment | 63 | bizjournals | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| GILEAD SCIENCES | 43,30 | +2,44 % | Maximieren Sie Ihren Ertrag in nur 30 Minuten! (Freenet +370% / Technotrans +100% / Gilead +120% ...) |
| PDL BIOPHARMA | 6,331 | +0,81 % | PDL BioPharma Misses Earnings Ests |
| STADA ARZNEIMITTEL | 33,555 | -0,93 % | STADA: Gute Zahlen und positive Analystenstimmen beflügeln Kurs |
| CELGENE | 95,79 | -0,02 % | Celgene: Apremilast For Psoriatic Arthritis Offers Upside |
| PFIZER | 22,565 | -1,03 % | Global Vision Selected by Pfizer for Worldwide Deployment of Automated Proofreading Solutions |
